| Literature DB >> 30798354 |
Zachary A Sorrentino1, Benoit I Giasson1, Paramita Chakrabarty2.
Abstract
α-Synuclein is a soluble protein that is present in abundance in the brain, though its normal function in the healthy brain is poorly defined. Intraneuronal inclusions of α-synuclein, commonly referred to as Lewy pathology, are pathological hallmarks of a spectrum of neurodegenerative disorders referred to as α-synucleinopathies. Though α-synuclein is expressed predominantly in neurons, α-synuclein aggregates in astrocytes are a common feature in these neurodegenerative diseases. How and why α-synuclein ends up in the astrocytes and the consequences of this dysfunctional proteostasis in immune cells is a major area of research that can have far-reaching implications for future immunobiotherapies in α-synucleinopathies. Accumulation of aggregated α-synuclein can disrupt astrocyte function in general and, more importantly, can contribute to neurodegeneration in α-synucleinopathies through various pathways. Here, we summarize our current knowledge on how astrocytic α-synucleinopathy affects CNS function in health and disease and propose a model of neuroglial connectome altered by α-synuclein proteostasis that might be amenable to immune-based therapies.Entities:
Keywords: Astrocyte heterogeneity; Exosome; Glial cytoplasmic inclusion; Lewy body; NAC domain; Neurodegeneration; Therapy; Transmission; Tunneling nanotube; α-Synuclein; αSyn 3H11
Year: 2019 PMID: 30798354 PMCID: PMC6571045 DOI: 10.1007/s00401-019-01977-2
Source DB: PubMed Journal: Acta Neuropathol ISSN: 0001-6322 Impact factor: 17.088